Boston Therapeutics is
developing a pipeline of novel compounds to address unmet medical needs in
diabetes. The company’s current product pipeline is focused on developing and
commercializing the therapeutic molecules PAZ320 for patients with diabetes; and
IPOXYNT for a wide rand of indications such as anemia and blood loss (injury),
cardiovascular disease, and surgical blood supplementation.
Boston Therapeutics’
technology platform in applied carbohydrate chemistry has been pioneered by
company CEO Dr. David Platt, who for the last 20 years has worked alongside
scientific collaborators to safely address medical needs for oral and
injectable applications.
Dr. Platt is recognized
worldwide as an expert in carbohydrate chemistry and has led two drug candidates
from concept to human clinical trials. He also founded three publicly traded
companies: Pro-Pharmaceuticals, Inc., SafeScience, Inc., and International Gene
Group. Dr. Platt’s guidance is supported by an executive management team with
more than 100 years of combined experience.
Providing additional
expertise, Boston Therapeutics has established a scientific advisory team with
extensive expertise in complex carbohydrate chemistry, regulatory, and clinical
development, with multiple submissions and approvals to U.S. Food and Drug
Administration.
Under this leadership,
Boston Therapeutics anticipates initiating a pivotal phase 3 study of PAZ320.
The two-year study, to be conducted in the U.S., Europe, Hong Kong, Korea, and
China, will be evaluate the effects of the drug candidate on glucose and
hemoglobin A1c (HbA1c) in approximately 300 Type 2 patients currently taking
metformin.
In an earlier phase 2 study,
PAZ320 achieved a 40 percent reduction in post-meal blood glucose levels with
no serious adverse events.
For additional information,
visit www.BostonTI.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
